The DOI matches its Crossref record.
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
Abstract
The efficacy and toxicity of leucovorin 500 mg/m2 administered intravenously (IV) over 30 minutes daily for five days followed in one hour by fluorouracil (5-FU) 375 mg/m2 administered IV daily for five days, each given every 3 weeks, was assessed in 54 previously treated patients with metastatic breast cancer. An overall objective response rate of 24% was achieved (95% confidence interval, 13% to 38%), with an additional 56% of patients maintaining stable disease. Eleven of 12 patients who responded had received previous 5-FU therapy. Toxicity of this regimen included grade 3 diarrhea in 13%, grade 3 or 4 mucositis in 33%, grade 3 or 4 granulocytopenia in 65%, and grade 3 or 4 thrombocytopenia in 19%. Delay of treatment was required for hematologic toxicity in 44 patients. Thirty-eight patients required dose reductions due to toxicity. Biochemical evaluation of tumor biopsy specimens obtained from 17 patients used as their own controls with and without leucovorin was performed. These studies reveal an increased stabilization of the 5-fluorodeoxyuridylate (FdUMP)-thymidylate synthase (TS) folate ternary complex with the addition of leucovorin. There was a 71% +/- 14% occupancy or inhibition of the enzyme with the use of both 5-FU and leucovorin, v 30% +/- 13% for 5-FU alone (P2 less than .037). The percent TS bound in responding patients was substantially higher than in those patients with progressive disease. Finally, the mean total tumor TS pre-therapy in seven patients was 31 fmol/mg compared with a mean of 81 fmol/mg in these same seven patients 24 hours after therapy. This 2.6-fold increase suggests that there is an induction of the enzyme, TS, with 5-FU treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008) · Molecules · doi:10.3390/molecules13081551 · Cited by 771
Leichman, C. G., Lenz, H. J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., & Danenberg, P. V. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3223 · Cited by 475
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
Peters, G. J., Backus, H. H. J., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C. L., Smid, K., Lunec, J., Calvert, A. H., Marsh, S., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00082-0 · Cited by 420
Colorectal Carcinoma: Diagnostic, Prognostic, and Molecular Features
Compton, C. C. (2003) · Modern Pathology · doi:10.1097/01.mp.0000062859.46942.93 · Cited by 403
Metadata
- Authors
- Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., & Allegra, C. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-07
- Volume
- 7
- Issue
- 7
- Pages
- 890-899
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2296462761
- Cited by
- 241
- References
- 0
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.1989.7.7.890
- The paper
- Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., & Allegra, C. J. (1989). Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1989.7.7.890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.